3Harlozinska A. Progress in mo lecularmechanisms of tumormletastasis and angiogenesis[J ]. Anticancer Res, 2005, 25 : 3327.
4Chodorowska G, Chodorowski J, W ysokinski A. Vascular endothelial growth factor(VEGF) in physiological and pathological conditions[J]. Ann Univ Mariae Curie Sklodow ska [Med], 2004, 59: 8.
5De Falco S, Ggante B, Persico M G. Stucture and function of placental growth factor [ J ]. Trends Cardiovasc Med, 2002, 12(6) : 241.
6Larcher F, Franco M, Bolontrade M, et al. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis[J]. Mol Carcinog, 2003, 37(2): 83.
7Fitzpatric T E, Lash G E, Yanaihara A, et al. Inhibition of breast carcinoma and trophobtast cell invasiveness by vascular endothelial growth factor[J]. Exp Cell Res, 2003, 283(2) : 247.
8Matsumoto K, Suzuki K, Koike H, et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia [ J ]. Anticancer Res, 2003, 23 (5A) : 3767.
9Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PLGF) and its reeerptor Flt-1 (VEGFR-1): novel thetapeutic targets for angiogenie disorders[J]. Ann N Y Acad Sci, 2002, 979: 80.
10Chen C N, Hsieh F J, Cheng Y M, et al. The significance of placenta gtoewth factor in angioganesis and clinical outcome of human gastric cancer[J]. Cancer Lett, 2004, 213: 73.
8Twabe T, Harada T, Terakawa N. Role of cytokines in endometriosis associated infertility[J]. Gynecol Obstet Invest, 2007, 53(2): 19-25.
9Leyendecker G, Wildt L, Mall G. The pathophysiology of endometri- osis and adenomyosis : tissue injury anti repair[J]. Arch Gynecol Ob- stet, 2009,280(4) : 529-538.
10l,iu X, Nie J, Guo SW. Elevated immunoreaetivity to tissue factor and its association with dysmenorrheal severity and the amount of menses in adenomyosis[J]. Hum Reprod,2011,26(2) :337-345.
